Ruxolitinib free base | CAS#941678-49-5 | JAK Inhibitor

MedKoo Cat#: 201512 | Name: Ruxolitinib free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ruxolitinib, also known as INC424 and INCB18424 or INCB018424, is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.

Chemical Structure

Ruxolitinib free base

CAS#941678-49-5 (free base)

Theoretical Analysis

MedKoo Cat#: 201512

Name: Ruxolitinib free base

CAS#: 941678-49-5 (free base)

Chemical Formula: C17H18N6

Exact Mass: 306.1592

Molecular Weight: 306.37

Elemental Analysis: C, 66.65; H, 5.92; N, 27.43

Price and Availability

Size	Price	Availability
10mg	USD 90.00	Ready to ship
200mg	USD 250.00	Ready to ship
500mg	USD 450.00	Ready to Ship
1g	USD 750.00	Ready to ship
2g	USD 1,350.00	Ready to Ship
5g	USD 2,950.00	Ready to Ship
10g	USD 5,250.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

941678-49-5 (free base) 1092939-17-7 (phosphate)

Synonym

INCB018424; INCB 018424; INCB-018424; INC424; INC424; INC-424; INCB18424; INCB 18424; INCB-18424; trade name:J akafi and Jakavi

IUPAC/Chemical Name

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

InChi Key

HFNKQEVNSGCOJV-OAHLLOKOSA-N

InChi Code

InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1

SMILES Code

N#CC[C@@H](N1N=CC(C2=C3C(NC=C3)=NC=N2)=C1)C4CCCC4

Appearance

White to light yellow solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#X7P07R31

View CoA: current batch, Lot#T7K08C28

QC Data

View QC data: current batch, Lot#T7K08C28

View QC data: current batch, Lot#X7P07R31

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Ruxolitinib is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy.

In vitro activity:

Ruxolitinib exhibited significant in vitro activity against Nalm-6 cells. It dose-dependently inhibited cell proliferation, induced cell cycle arrest at G0/G1 phase, and promoted apoptosis in MLL-r ALL cells. Ruxolitinib inactivated the JAK/STAT signaling pathway, contributing to its anti-proliferative and pro-apoptotic effects. Ruxolitinib is a promising therapeutic agent for MLL-r leukemia. Reference: Transl Pediatr. 2023 Jun 30;12(6):1088-1097. https://pubmed.ncbi.nlm.nih.gov/37427069/

In vivo activity:

Ruxolitinib was administered to a patient with Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (HLH) characterized by EBV infection within CD8+ T cells. Ruxolitinib treatment led to the resolution of symptoms and improvement in HLH parameters, demonstrating its in vivo activity in controlling EBV-associated HLH, particularly in cases where rituximab and corticosteroids may be insufficient. Reference: lin Transl Immunology. 2023 Jul 25;12(7):e1459. https://pubmed.ncbi.nlm.nih.gov/37497193/

	Solvent	mg/mL	mM
Solubility
	DMSO	5.0	16.30
	DMF	5.0	16.30
	Ethanol	13.0	42.40

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 306.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Chen L, Zhu MY, Wang GX, Lu LL, Lin L, Lei L, Wu T. Ruxolitinib ameliorated coxsackievirus B3-induced acute viral myocarditis by suppressing the JAK-STAT pathway. Int Immunopharmacol. 2023 Aug 25;124(Pt A):110797. doi: 10.1016/j.intimp.2023.110797. Epub ahead of print. PMID: 37634445. 2. Liao XY, Zhou DH, Fang JP, Qiu KY. Ruxolitinib inhibits the proliferation and induces the apoptosis of MLL-r ALL cells through inactivating JAK/STAT signaling pathway. Transl Pediatr. 2023 Jun 30;12(6):1088-1097. doi: 10.21037/tp-23-16. Epub 2023 Jun 14. PMID: 37427069; PMCID: PMC10326758. 3. Ali S, Choo S, Hosking L, Smith A, Hughes T. A case of T-cell-Epstein-Barr virus-haemophagocytic lymphohistiocytosis and sustained remission following ruxolitinib therapy. Clin Transl Immunology. 2023 Jul 25;12(7):e1459. doi: 10.1002/cti2.1459. PMID: 37497193; PMCID: PMC10368518. 4. Berenson JR, Kim C, Bujarski S, To J, Spektor TM, Martinez D, Turner C, Ghermezi M, Eades BM, Swift RA, Schwartz G, Eshaghian S, Moss RA, Lim S, Vescio R. A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients. Hematol Oncol. 2022 Dec;40(5):906-913. doi: 10.1002/hon.3066. Epub 2022 Aug 14. PMID: 35946431.

In vitro protocol:

In vivo protocol:

1. Ali S, Choo S, Hosking L, Smith A, Hughes T. A case of T-cell-Epstein-Barr virus-haemophagocytic lymphohistiocytosis and sustained remission following ruxolitinib therapy. Clin Transl Immunology. 2023 Jul 25;12(7):e1459. doi: 10.1002/cti2.1459. PMID: 37497193; PMCID: PMC10368518. 2. Berenson JR, Kim C, Bujarski S, To J, Spektor TM, Martinez D, Turner C, Ghermezi M, Eades BM, Swift RA, Schwartz G, Eshaghian S, Moss RA, Lim S, Vescio R. A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients. Hematol Oncol. 2022 Dec;40(5):906-913. doi: 10.1002/hon.3066. Epub 2022 Aug 14. PMID: 35946431.

1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Ruxolitinib. 2023 Dec 15. PMID: 29999923. 2: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Ruxolitinib. 2022 Aug 30. PMID: 31643852. 3: Kashetsky N, Turchin I. Utilization of Topical Ruxolitinib in Dermatology: A Review. Skin Therapy Lett. 2023 May;28(3):8-13. PMID: 37339609. 4: Harrison CN, Schaap N, Mesa RA. Management of myelofibrosis after ruxolitinib failure. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. PMID: 32198525; PMCID: PMC7237516. 5: Bai Y, Wang W, Yin P, Gao J, Na L, Sun Y, Wang Z, Zhang Z, Zhao C. Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice. Int J Biol Sci. 2020 Jan 1;16(2):194-203. doi: 10.7150/ijbs.39024. PMID: 31929748; PMCID: PMC6949153. 6: Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557. PMID: 22375971; PMCID: PMC4822164. 7: Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ. Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review. Clin Pharmacokinet. 2023 Apr;62(4):559-571. doi: 10.1007/s40262-023-01225-7. Epub 2023 Mar 31. PMID: 37000342; PMCID: PMC10064968. 8: Algeri M, Becilli M, Locatelli F. Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease. Expert Rev Clin Immunol. 2023 Jul-Dec;19(11):1299-1313. doi: 10.1080/1744666X.2023.2249230. Epub 2023 Aug 22. PMID: 37606511. 9: Verstovsek S, Mesa RA, Livingston RA, Hu W, Mascarenhas J. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. J Hematol Oncol. 2023 Jul 27;16(1):82. doi: 10.1186/s13045-023-01471-z. PMID: 37501130; PMCID: PMC10373260. 10: Becker H, Engelhardt M, von Bubnoff N, Wäsch R. Ruxolitinib. Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16. PMID: 24756798. 11: Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002. PMID: 25629741; PMCID: PMC4358820. 12: Ali H, Salhotra A, Modi B, Nakamura R. Ruxolitinib for the treatment of graft-versus-host disease. Expert Rev Clin Immunol. 2020 Apr;16(4):347-359. doi: 10.1080/1744666X.2020.1740592. Epub 2020 Apr 1. PMID: 32153201. 13: Fan S, Huo WX, Yang Y, Shen MZ, Mo XD. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis. Front Immunol. 2022 Aug 4;13:954268. doi: 10.3389/fimmu.2022.954268. PMID: 35990629; PMCID: PMC9386528. 14: Zhang Q, Zhao YZ, Ma HH, Wang D, Cui L, Li WJ, Wei A, Wang CJ, Wang TY, Li ZG, Zhang R. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis. Blood. 2022 Jun 16;139(24):3493-3504. doi: 10.1182/blood.2021014860. PMID: 35344583. 15: Li Y, Zhu S, Liu W, Ming J, Wang X, Hu X. Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to. Ann Hematol. 2020 Jun;99(6):1161-1176. doi: 10.1007/s00277-020-04028-z. Epub 2020 Apr 24. PMID: 32333155; PMCID: PMC7237512. 16: Grossmann MC, Haidari W, Feldman SR. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo. J Drugs Dermatol. 2023 Jul 1;22(7):664-667. doi: 10.36849/JDD.7268. PMID: 37410047. 17: Pemmaraju N, Bose P, Rampal R, Gerds AT, Fleischman A, Verstovsek S. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma. 2023 Jun;64(6):1063-1081. doi: 10.1080/10428194.2023.2196593. Epub 2023 Apr 20. PMID: 37081809. 18: Kang C. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. Drugs. 2024 May;84(5):579-586. doi: 10.1007/s40265-024-02027-2. Epub 2024 Apr 16. Erratum in: Drugs. 2024 Jun;84(6):745. doi: 10.1007/s40265-024-02055-y. PMID: 38625661; PMCID: PMC11189965. 19: Abedin SM, Hamadani M. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. Expert Opin Investig Drugs. 2020 May;29(5):423-427. doi: 10.1080/13543784.2020.1757069. Epub 2020 Apr 19. PMID: 32293938. 20: Ibrahim U, Petrone GEM, Mascarenhas J, Keyzner A. Peritransplantation Use of Ruxolitinib in Myelofibrosis. Biol Blood Marrow Transplant. 2020 Dec;26(12):2177-2180. doi: 10.1016/j.bbmt.2020.08.015. Epub 2020 Aug 18. PMID: 32818555.